Previous Article | Next Article 
Journal of Virology, September 1999, p. 7193-7198, Vol. 73, No. 9
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Picornavirus Receptor Down-Regulation by
Plasminogen Activator Inhibitor Type 2
D. R.
Shafren,1,*
J.
Gardner,2
V. H.
Mann,3
T. M.
Antalis,3 and
A.
Suhrbier2
Picornaviral Research Unit, Discipline of
Immunology and Microbiology, Faculty of Medicine and Health Sciences,
University of Newcastle, Newcastle, New South Wales
2300,1 and Cellular Oncology
Laboratory3 and Australian Centre
for International & Tropical Health & Nutrition,2 Queensland Institute of Medical
Research and University of Queensland, Brisbane, Queensland 4029, Australia
Received 4 February 1999/Accepted 21 May 1999
 |
ABSTRACT |
Therapeutic interference with virus-cell surface receptor
interactions represents a viable antiviral strategy. Here we
demonstrate that cytoplasmic expression of the serine protease
inhibitor (serpin), plasminogen activator inhibitor type 2 (PAI-2),
affords a high level of protection from lytic infection by multiple
human picornaviruses. The antiviral action of PAI-2 was mediated
primarily through transcriptional down-regulation of the following
virus receptors: intercellular adhesion molecule 1 (ICAM-1, a cellular
receptor for the major group of rhinoviruses), decay-accelerating
factor (a cellular receptor for echoviruses and coxsackieviruses), and
to a lesser extent the coxsackie-adenovirus receptor protein (a
cellular receptor for group B coxsackieviruses and group C
adenoviruses). Expression of related cell surface receptors, including
membrane cofactor protein and the poliovirus receptor, remained
unaffected. These findings suggest that PAI-2 and/or related serpins
may form the basis of novel antiviral strategies against picornavirus
infections and also therapeutic interventions against ICAM-1-mediated
respiratory inflammation.
 |
INTRODUCTION |
Picornaviruses are small, spherical,
naked viruses (20 to 25 nm) containing positive-sense genomic RNA and
comprise a genus of the family Picornaviridae. The two
largest subgroups are rhinoviruses and enteroviruses. There are ~100
rhinovirus serotypes, which collectively constitute the most important
cause of mild upper respiratory illnesses in adults. The human
enteroviruses consist of polioviruses (3 serotypes), echoviruses (34 serotypes), group A coxsackieviruses (24 serotypes), and group B
coxsackieviruses (6 serotypes). The human enteroviruses are ubiquitous;
transmitted primarily by the oral-fecal route, they are capable of
producing a wide range of clinical syndromes varying in severity. They
are mainly found in the gastrointestinal tracts of infected individuals but also have the potential to infect the meninges, central nervous system, myocardium, pericardium, striated muscles, respiratory tract,
and skin (23).
Identification and molecular characterization of virus-specific
receptors and receptor-mediated processes are important not only
because receptors determine host range, susceptibility to infection,
and pathogenesis but also because virus receptors constitute potential
targets for antiviral therapy. Three major groups of cell surface
molecules have been shown to be involved with distinct stages of
picornaviral cell attachment and membrane penetration: the
immunoglobulin-like supergene family, complement regulatory proteins,
and integrins. The poliovirus receptor (PVR) (24), intercellular adhesion molecule 1 (ICAM-1) (16), and
coxsackievirus-adenovirus receptor (CAR) (8, 36) are all
members of the immunoglobulin-like supergene family (Fig.
1) and are able to facilitate productive cell infection by polioviruses (24), a major group of
rhinoviruses (16), and some group A (31) and
group B (8, 33, 36) coxsackieviruses, respectively. In
contrast, the complement regulatory protein, decay-accelerating factor
(DAF) (28) (Fig. 1), is employed as an attachment or
sequestering receptor by many enteroviruses (6, 7, 17, 30, 32,
41) but cannot by itself mediate entry of virus into the cell
(7, 30) unless cross-linked by specific antibody (34,
34a). Additionally, a number of integrins have been shown to bind
human picornaviruses, but their role in viral cell entry is uncertain
(1, 5, 29). Recently, a number of picornaviruses have been
shown to employ complexes of the above-mentioned receptors to enter
cells, these receptor complexes consisting of distinct attachment and
cell internalizing components (32, 33).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of structures of the virus
receptors ICAM-1, PVR, CAR, MCP, and DAF. ICAM-1, PVR, and CAR belong
to the immunoglobulin supergene family, and MCP and DAF are complement
regulatory proteins. ICAM-1 is an internalization receptor for
rhinoviruses and some group A coxsackieviruses. CAR is an
internalization receptor for group B coxsackieviruses. DAF is a
sequestration receptor for coxsackieviruses, echoviruses, and
enteroviruses. C2, constant region 2; V, variable region; SCR, short
consensus repeat.
|
|
The cellular expression of many picornavirus receptors is strongly
influenced by the action of inflammatory cytokines (10, 26, 35,
37). Human rhinoviruses (HRVs) enhance their own dissemination by
up-regulating the cell surface expression of ICAM-1 on neighboring
cells through cytokine induction. ICAM-1 is highly susceptible to
up-regulation via the inflammatory cytokines tumor necrosis factor
alpha (TNF-
) and interleukin-1
(IL-1
) (37), and
during initial stages of cellular lytic infection by HRVs, cytokines
such as TNF-
and IL-1
are released by infected cells
(35). Furthermore, the expression of CAR on the surface of
colon carcinoma cells is markedly increased by the action of TNF-
(1a).
The expression of DAF, a major picornavirus attachment receptor, has
been shown to be significantly up-regulated by the action of TNF-
(10, 26). In contrast, another member of the complement regulatory protein family, membrane cofactor protein (MCP; CD46), which
is also a cellular receptor for measles viruses, is resistant to
TNF-
-induced up-regulation (10, 26, 38). Thus, the
ability to negate TNF-
-induced up-regulation of cellular virus
receptors might be regarded a potential antiviral strategy for
controlling human picornavirus infections.
TNF-
, in addition to up-regulating numerous cellular proteins, is
also able to promote apoptosis in many cells (40). Recently, cells expressing plasminogen activator inhibitor type 2 (PAI-2) were
shown to be protected from TNF-
-induced apoptosis (13, 21). PAI-2 is a serine proteinase inhibitor (serpin), which is a
major product of macrophages in response to endotoxin and inflammatory
cytokines (20). Under physiological conditions, PAI-2
expression is limited to a select number of cell types, which include
differentiated keratinocytes, activated monocytes and macrophages,
placental trophoblasts, and some tumor cell lines (20).
PAI-2 is well characterized as an inhibitor of the extracellular proteinase urokinase-type plasminogen activator (20, 39). Recently, an additional, distinct, intracellular function for PAI-2 as
a regulator of the intracellular signal transduction pathway(s) has
been postulated (3, 13). Intracellular PAI-2 expression in
HeLa cells was associated with resistance to TNF-
-mediated apoptosis
(13) and with increased alpha/beta interferon (IFN-
/
) activity (3). PAI-2 is a member of the ovalbumin group of
serpins (ov-serpins), which lack hydrophobic signal sequences. This
results in inefficient secretion and translocation and thus a primarily cytoplasmic location of these proteins. In the case of HeLa cells expressing PAI-2, no secreted PAI-2 is detectable. Apart from PAI-2, a
number of other ov-serpins have now been shown to have cytoplasmic
functions; these include CrmA (15), protease inhibitor 9 (9), and protease inhibitor 6 (27).
Here we show that expression of PAI-2 in HeLa cells significantly
reduced picornavirus infection through transcriptional down-regulation of the expression of TNF-
-inducible virus receptors. These findings may find application in the development of a novel serpin-based antiviral strategies for control of enteric picornavirus infections, and also for the therapeutic reduction of ICAM-1-mediated respiratory inflammations.
 |
MATERIALS AND METHODS |
Cells and viruses.
Echovirus type 7 (EH7; Wallace),
poliovirus type 1 (PV1; Sabin), coxsackievirus A21 (CVA21; KuyKendall),
coxsackievirus B3 (CVB3; Nancy), and HeLa B cells were obtained from
Margery Kennett, Enterorespiratory Laboratory, Fairfield Hospital,
Melbourne, Victoria, Australia. HRV type 14 (HRV14) was obtained from
the American Type Culture Collection. All viruses were grown in HeLa B cells.
A panel of individual cloned HeLa cell lines expressing sense (S1a and
S1b) and antisense (A2/7) PAI-2 cDNA was generated as previously
described (13) by inserting a DNA fragment containing the
entire PAI-2 coding sequence and the 3' untranslated region in both
orientations into the expression vector pRcCMV under control of the
constitutive cytomegalovirus V promoter. Stable transfectants containing these constructs were selected by resistance to G418 and
characterized by Northern blot, immunoblot, and immunofluorescence analyses (13, 14). HeLa and A2/7 cells express no detectable PAI-2 mRNA or protein. S1a and S1b cell lines each express cytoplasmic PAI-2 at levels similar to or less than those detected in activated monocytic cells (13).
Antibodies.
The anti-ICAM-1 monoclonal antibody (MAb) WEHI
(11) was obtained from Andrew Boyd, Queensland Institute of
Medical Research, Brisbane, Australia. The anti-DAF MAbs IA10, VIIIA7,
and IIH6 (18) were generous gifts from Taroh Kinoshita,
Department of Immunoregulation, Osaka University, Osaka, Japan; MAb IH4
and anti-MCP MAb E4.3 (12) were from Bruce Loveland, Austin
Research Institute, Heidelberg, Victoria, Australia. The anti-PVR MAb
280 (25) was supplied by Philip Minor, National Institute
for Biological Standards and Control, Potters Bar, United Kingdom, and
the anti-CAR MAb (8) was from Jeffery Bergelson, Dana-Farber
Cancer Institute, Boston, Mass.
Virus infectivity assay.
Cell monolayers in 96-well culture
plates were challenged with 100 µl of 10-fold serial dilutions of the
above-mentioned picornaviruses and then incubated at 37°C for 48 h. To quantitate cell survival, monolayers were stained with a crystal
violet-methanol solution and washed with distilled water, and the
plates were read at a wavelength of 540 nm. Results are expressed as
mean percentages of cell lysis relative to the uninfected control cell
monolayers of triplicate wells + standard deviation.
Radiolabeled virus binding assays.
Viruses were radiolabeled
in Dulbecco's modified essential medium containing
[35S]methionine and purified by velocity centrifugation
in 5 to 30% sucrose gradients as previously described (32).
Monolayers of PAI-2-expressing S1a and S1b cells and parental HeLa
cells were incubated with radiolabeled viruses (2 × 104 to 5 × 104 cpm) in serum-free
Dulbecco's modified essential medium for 1 h at 37°C. After
three washes, the cell monolayers were dissolved in 200 µl of 0.2 M
NaOH-1.0% sodium dodecyl sulfate (SDS). The amount of labeled virus
bound was measured by liquid scintillation counting.
Flow cytometry.
Cells (5 × 105) were
incubated with the appropriate MAbs (5.0 µg/ml) diluted in
phosphate-buffered saline (PBS) containing 1% bovine serum albumin
(PBS-BSA) at 0°C for 30 min, after which the cells were washed with
5.0 ml of PBS-BSA. The cells were then pelleted at 1,000 × g for 5 min and resuspended in 100 µl of
phycoerythrin-conjugated goat anti-mouse immunoglobulin G (heavy plus
light chains) (Silenus, Melbourne, Victoria, Australia) diluted in
PBS-BSA. After incubation at 0°C for 30 min, the cells were washed
and pelleted as described above, resuspended in PBS-BSA, and analyzed
with a FACStar analyzer (Becton Dickinson, Sydney, New South Wales, Australia).
Surface biotinylation and immunoprecipitation.
Cells (5 × 106) were detached from the surface of plastic tissue
culture flasks by using an EDTA solution and washed once in PBS. Washed
cells were resuspended into 3 ml of biotinylation buffer (10 nM sodium
borate [pH 8.8], 150 nM NaCl). Biotin-amidocaproate N-hydroxysuccinimide ester was added to 50 µg/ml, and the
sample stood at room temperature for 15 min. The reaction was
terminated by the addition of NH4Cl to 10 mM. Cells were
washed twice in PBS and resuspended into buffer A (138 mM NaCl, 2.9 mM
KCl, 0.5 mM MgCl2, 12 mM NaHCO3, 0.3 mM
NaH2PO4, 5.5 mM glucose, 10 mM HEPES [pH
7.4]). Cell lysates were placed on ice for 60 min and then centrifuged
at 15,000 × g for 15 min to remove detergent-insoluble material. Soluble lysates were precleared with rabbit anti-mouse immunoglobulin G coupled to Sepharose 4B. Immunocomplexes were washed
three times with lysis buffer and resolved (reduced) by SDS-polyacrylamide gel electrophoresis. Resolved proteins were electrophoretically transferred to nitrocellulose membranes.
Streptavidin-biotin-horseradish peroxidase complexes were used to probe
the membrane, and labeled proteins were visualized by using enhanced
chemiluminescence (Amersham Life Sciences, Little Chalfont, United Kingdom).
Northern blot analysis.
Total RNA isolated from S1a, S1b,
A2/7, and parental HeLa cells was separated by denaturing gel
electrophoresis and transferred to Hybond-N nylon membranes as
described elsewhere (2). The blot was hybridized with
[32P]dCTP-labeled purified DNA fragments encoding cDNAs
for ICAM-1 (30), DAF (30), CAR (8),
and PVR (24). Blots were hybridized at 65°C and washed to
a final stringency of 0.1× SSC (1× SSC is 0.15 M NaCl plus 0.015 M
sodium citrate)-0.1% SDS at 65°C. The level of 18S rRNA was used as
a measure of RNA loading in each lane.
 |
RESULTS |
PAI-2 expression inhibits HeLa cell lytic infection by many
picornaviruses.
Monolayers of S1a, S1b, A2/7, and parental HeLa
cells were challenged (105 PFU/well) with PV1, HRV14, E7,
CAV21, and CVB3 and examined for cytopathic effect following a 48-h
incubation period. The cell lines not expressing PAI-2 (HeLa and A2/7)
were susceptible to lytic infection by all of these picornaviruses
(Fig. 2). In contrast, PAI-2-expressing
S1a cells were refractory to lytic infection by HRV14, E7, CAV21, and
CVB3 but not PV1 (Fig. 2).

View larger version (94K):
[in this window]
[in a new window]
|
FIG. 2.
Picornavirus-induced lytic infection of PAI-2-expressing
S1a cells and control A2/7 and parental HeLa cells. Monolayers of S1a,
A2/7, and HeLa cells in 96-well culture plates were inoculated
(approximately 105 PFU/well) with PV1, HRV14, E7, CAV21,
and CVB3. Following incubation for 48 h at 37°C, the cell
monolayers were inspected for signs of cell lysis and then photographed
at an original magnification of ×20.
|
|
To determine whether infection of PAI-2-expressing cells was
noncytopathic but still productive, monolayers of HeLa and S1a
cells in
six-well plates were infected with inocula of 10
5 and
10
3 PFU of CVB3. Following incubation for 24 h, cell
lysis was evident
only in the inoculated HeLa cells. Analysis of
infectious virus
production by plaque assay revealed that S1a
cells yielded titers
attributable to that of the input virus, whereas
HeLa cell lysates
yielded increases of 10
3- and
10
5-fold, respectively, over the input inoculum (data not
shown).
To further quantitate the antiviral effect of PAI-2 expression,
monolayers of HeLa, A2/7, and S1a cells were infected with
10-fold
serial dilutions of PV1, HRV14, E7, CAV21, and CVB3. HeLa
and A2/7
cells showed higher levels of cell lysis than S1a cells
for all
dilutions of HRV14, E7, CAV21, and CVB3 (Fig.
3). S1b
cells behaved similarly to S1a
cells in these assays (data not
shown). At low dilutions (or high
multiplicity of infection [MOI])
of PV1, no difference between
cytopathic effect of S1a cells and
control cells was observed; however,
at high dilutions of virus
(low MOI), S1a cells showed increased
survival (low percent lysis)
relative to control lines (Fig.
3).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 3.
Dose-dependent picornavirus-induced lytic infection of
S1a, A2/7, and HeLa cells, using a range of input multiplicities of
PV1, HRV14, E7, CAV21, and CVB3.
|
|
The lower cell lysis values for E7 and HRV infection of control cell
lines at high virus dilutions than for CAV21 and CVB3
infection reflect
a lower replication competence of E7 and HRV
in HeLa cells and thus
less lysis within the 48-h assay
period.
Thus, HeLa and A2/7 cells were substantially more susceptible than
PAI-2-expressing cells to the cytopathic effects of HRV14,
E7,
CAV21, and CVB3 infection. Picornaviral replication appeared
not to be
modified by PAI-2 cytoplasmic expression, as HeLa and
PAI-2-expressing
S1a cells yielded comparable levels of infectious
CAV21 and CVB3
when transfected with CAV21 and CVB3 viral RNAs,
respectively
(data not
shown).
Reduced binding of picornaviruses to PAI-2-expressing cells.
To determine whether inhibition of picornavirus lytic infection in S1a
and S1b cells was due to interference with cellular attachment,
preparations of gradient-purified picornaviruses were radiolabeled
(Fig. 4A) and incubated with S1a, S1b,
and HeLa cells to monitor relative levels of virus-cell surface
binding. Cellular attachment of E7, HRV14, CAV21, and CVB3 was reduced
by between 80 and 95% in S1a and S1b cells compared to HeLa controls
(Fig. 4B). PV1 bound equally to S1a, S1b, and HeLa cell lines, albeit with a slight increase in binding to S1b cells compared with HeLa cells
(Fig. 4B).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 4.
Picornavirus binding to S1a, A2/7, and parental HeLa
cells. (A) 35S-labeled preparations of PV1, HRV14, E7,
CAV21, and CVB3 were separated on a 15% slab SDS-polyacrylamide gel,
and individual proteins identified by autoradiography. (B) Monolayers
of PAI-2-expressing S1a and S1b cells and parental HeLa cells were
incubated with radiolabeled viruses and washed, and the amount of
labeled virus bound was measured by liquid scintillation counting.
Results are expressed as the mean of triplicate wells + standard
deviation.
|
|
The overall pattern of reduced virus binding to the panel of cells was
similar to the pattern observed for inhibition of virus-induced
lytic
infection shown in Fig.
2 and
3, suggesting that the presence
of PAI-2
reduced the surface expression of picornavirus cellular
receptors.
PAI-2 reduces surface expression of picornavirus receptors.
To
determine whether PAI-2-transfected cells expressed lower levels of
virus receptors, which would result in less virus binding (Fig. 4) and
less cell infection (Fig. 2 and 3), the levels of the picornavirus
receptor molecules PVR, CAR, DAF, and ICAM-1 were assessed by flow
cytometry. The cellular receptor of the unrelated measles virus, MCP,
was included as a control. Measurement of the mean peak fluorescence
intensities showed that expression of CAR, DAF, and ICAM-1 on the
surface of S1a and S1b cells compared to A2/7 cells was reduced by 50 to 90% (Fig. 5A). The surface expression
of PVR and MCP was similar among all cell lines, indicating that these
receptors were unaffected by PAI-2 expression. (Results for the parent
HeLa cell line were similar to those for A2/7 cells in these assays
[data not shown]). The slight increase in PV1 binding to S1b cells
observed in Fig. 4B was mirrored by a slight increase in the level of
PVR on S1b cells (Fig. 5A). The decreased picornavirus receptor
expression on the surface of PAI-2-expressing HeLa cells was not due to
an accident of the transfection and selection process, as the antisense
PAI-2 clone A2/7 (Fig. 5) and a chloramphenicol
acetyltransferase-expressing HeLa clone generated by the same protocol
as used for the S1a and S1b cells showed no signs of reduced surface
ICAM-1 expression (35a).

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis of picornavirus receptor expression on the
surface of S1a, S1b, and HeLa cells. (A) Flow cytometric analysis of
receptor surface expression. Suspensions of S1a, S1b, A2/7, and HeLa
cells were incubated with MAbs against the virus receptors PVR, ICAM-1,
DAF, CAR, and MCP. (B) Immunoprecipitation of biotinylated virus
receptors. S1a and A2/7 cells were surface biotinylated and then
immunoprecipitated with anti-DAF, anti-ICAM-1, and anti-CAR MAbs, as
indicated. Sizes are indicated in kilodaltons.
|
|
To confirm that PAI-2 selectively reduced surface expression of CAR,
DAF, and ICAM-1, S1a cells and A2/7 cells were surface
biotinylated and
immunoprecipitated with anti-DAF, anti-CAR, and
anti-ICAM-1 MAbs. The
level of surface expression of biotinylated
DAF and CAR was
significantly less on the surface of S1a cells
than on the surface of
A2/7 cells. ICAM-1 expression differed
dramatically between the two
cell lines, being undetectable on
the surface of S1a cells (Fig.
5B).
The reduction in CAR, DAF,
and ICAM-1 expression on the surface of
PAI-2-expressing S1a cells
(Fig.
5B) mirrored that detected by flow
cytometry (Fig.
5A).
These data clearly show a reduction in the expression of the
picornavirus receptors CAR, DAF, and ICAM-1 in PAI-2 expressing
cells,
while PVR and MCP were
unaffected.
PAI-2-mediated picornavirus receptor down-regulation occurs at the
transcriptional level.
To ascertain whether PAI-2-induced
picornavirus receptor down-regulation was mediated by transcriptional
or posttranscriptional activity, mRNA levels for ICAM-1, DAF, and PVR
were examined in PAI-2-expressing and control cell lines. Significant
levels of PVR mRNA were detected in each cell line (S1a, S1b, A2/7, and HeLa) independent of expression of PAI-2 (Fig.
6). ICAM-1 and DAF mRNAs were present in
HeLa and A2/7 cells, but no ICAM-1 or DAF mRNA was detected in
PAI-2-expressing S1a and S1b cells (Fig. 6). A marked reduction in the
CAR mRNA level was observed in the S1a cells but not in S1b cells (data
not shown). This may be due to the finding that S1a cells express
significantly higher levels of intracellular PAI-2 than S1b cells
(3a), which raises the possibility that the intracellular
threshold PAI-2 level required for CAR down-regulation is higher than
that needed for DAF and ICAM-1 down-regulation. The levels of the
loading control, 18S and 28S rRNAs, were comparable in all the samples.
These findings demonstrated that the reduction in the expression of
picornavirus receptors in PAI-2-expressing cells was due to a reduction
in their gene transcription.

View larger version (113K):
[in this window]
[in a new window]
|
FIG. 6.
Northern blot analysis of virus receptor expression in
PAI-2-expressing S1a and S1b cells and control A2/7 and HeLa cells.
Total RNA was isolated from each cell line, separated by denaturing gel
electrophoresis, and Northern blotted, and the membranes were probed
with radiolabeled cDNA fragments encoding each receptor. Levels of 18S
and 28S rRNAs are shown as a measure of RNA loading in each lane.
|
|
 |
DISCUSSION |
This study demonstrated that expression of PAI-2 protected the
highly permissive HeLa cells against lytic infection by selected human
picornaviruses (Fig. 2 and 3). The primary mode of action was a
PAI-2-dependent transcriptional down-regulation of the surface expression of three picornavirus cellular receptors, DAF, CAR, and
ICAM-1 (Fig. 6). The surface expression of other virus receptors, namely, PVR and MCP, although closely related to CAR/ICAM-1 and DAF
(Fig. 1), respectively, were unaffected by cytoplasmic expression of
PAI-2 (Fig. 5).
Cytoplasmic expression of PAI-2 has been shown to protect cells against
TNF-
-mediated apoptosis (13, 21), and here we show that
PAI-2 expression significantly reduced the surface expression of the
virus receptor molecules DAF, CAR, and ICAM-1, which are all known to
be TNF-
inducible (10, 26, 37). In contrast, PVR and MCP
were not inducible by TNF-
, and their expression was largely
unaffected by PAI-2 expression. The structural relatedness of PVR, CAR,
and ICAM-1 and of DAF and MCP (Fig. 1) appeared to have no bearing on
the PAI-2-mediated effects. Thus, PAI-2 appeared to selectively
down-regulate TNF-
-inducible receptors, although the expression of
the TNF-
-inducible HLA class I was not affected by PAI-2 expression
(data not shown). These experiments suggest that PAI-2 has activity as
a specific intracellular regulator of gene expression, consistent with
previous reports of a PAI-2-mediated influence on the signal
transduction pathway(s) (3, 13, 14).
Antalis et al. (3) recently described another phenotype of
PAI-2-expressing HeLa cells whereby the cells were protected from the
rapid cytopathic effects of alphavirus infection via a PAI-2-mediated
induction of constitutive IFN-
/
production (3). The
replication of many picornaviruses has been shown to be inhibited by
the action of IFN-
/
(19, 22). The antiviral action of
IFN-
/
may provide an explanation for the protection against
poliovirus lytic infection seen in PAI-2-expressing cells at low MOI
(Fig. 3), in the absence of receptor down-regulation or reduction in
viral binding (Fig. 4 and 5). The antipicornaviral activity of PAI-2
may thus be twofold: (i) the major component via receptor
down-regulation and reduction of viral binding and (ii) a minor
component via inhibition of viral replication through the action of
autocrine IFN-
/
.
Picornavirus infections are a major cause of morbidity in our
community, with symptoms ranging from the common cold to pericarditis. For many of these viruses, the large number of serotypes makes vaccine
development difficult. In recent years, much research effort has been
directed at characterizing the cellular receptors used by viruses and
the molecular basis of virus-receptor interactions, with the ultimate
aim of developing generic antiviral strategies. Here we show that a
specific serpin can transcriptionally down-regulate specific viral
receptors, illustrating the potential for novel serpin based antiviral
strategies for a large proportion of picornavirus infections.
ICAM-1 plays an important role in the pathogenesis of not only
rhinovirus infection but also Plasmodium falciparum
infection (4) and the exacerbations of asthma, chronic
bronchitis, and cystic fibrosis (42). ICAM-1 was the most
susceptible to the action of cytoplasmic PAI-2 expression, indicating
that PAI-2-based therapy may also find application in the reduction of
ICAM-1-mediated respiratory inflammations.
 |
ACKNOWLEDGMENTS |
We thank Margery Kennett for the stock picornaviral preparations,
and we thank Rebecca Ingham and Simone Cross for excellent technical assistance.
This research was supported by grants from the National Health and
Medical Research Council of Australia, Hunter Medical Research Foundation, Australian Center for International & Tropical Health & Nutrition, and the Australian Commonwealth AIDS Research Grants Program.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Picornaviral
Research Unit, Discipline of Immunology and Microbiology, Faculty of
Medicine and Health Sciences, University of Newcastle, Level 3, David
Maddison Clinical Sciences Building, Royal Newcastle Hospital,
Newcastle, New South Wales 2300, Australia. Phone: 61 2 4923 6158. Fax:
61 2 4923 6814. E-mail:
dshafren{at}mail.newcastle.edu.au.
 |
REFERENCES |
| 1.
|
Agrez, M. V.,
D. R. Shafren,
X. Gu,
K. Cox,
D. Sheppard, and R. D. Barry.
1997.
Integrin alpha v beta 6 enhances coxsackievirus B1 lytic infection of human colon cancer cells.
Virology
239:71-77[Medline].
|
| 1a.
| Agrez, M. V. Personal communication.
|
| 2.
|
Antalis, T. M., and J. L. Dickinson.
1992.
Control of plasminogen-activator inhibitor type 2 gene expression in the differentiation of monocytic cells.
Eur. J. Biochem.
205:203-209[Medline].
|
| 3.
|
Antalis, T. M.,
M. La Linn,
K. Donnan,
L. Mateo,
J. Gardner,
J. L. Dickinson,
K. Buttigieg, and A. Suhrbier.
1998.
The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming.
J. Exp. Med.
187:1799-1811[Abstract/Free Full Text].
|
| 3a.
| Antalis, T. M. Personal communication.
|
| 4.
|
Berendt, A. R.,
A. McDowall,
A. G. Craig,
P. A. Bates,
M. J. E. Sternberg,
K. Marsh,
C. I. Newbold, and N. Hogg.
1992.
The binding site on ICAM-1 for Plasmodium falciparum-infected erythrocytes overlaps, but is distinct from, the LFA-1-binding site.
Cell
68:71-81[Medline].
|
| 5.
|
Bergelson, J. M.,
M. P. Shepley,
B. M. Chan,
M. E. Hemler, and R. W. Finberg.
1992.
Identification of the integrin VLA-2 as a receptor for echovirus 1.
Science
255:1718-1720[Abstract/Free Full Text].
|
| 6.
|
Bergelson, J. M.,
B. M. Chan,
K. R. Solomon,
J. N. St. John, and R. W. Finberg.
1994.
Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses.
Proc. Natl. Acad. Sci. USA
91:6245-6249[Abstract/Free Full Text].
|
| 7.
|
Bergelson, J. M.,
J. G. Mohanty,
R. L. Crowell,
N. F. St. John,
D. M. Lublin, and R. W. Finberg.
1995.
Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55).
J. Virol.
69:1903-1906[Abstract].
|
| 8.
|
Bergelson, J. M.,
J. A. Cunningham,
G. Droguett,
E. A. Kurt-Jones,
A. Krithivas,
J. S. Hong,
M. S. Horwitz,
R. C. Crowell, and R. W. Finberg.
1997.
Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5.
Science
275:1320-1323[Abstract/Free Full Text].
|
| 9.
|
Bird, C. H.,
V. R. Sutton,
J. Sun,
C. E. Hirst,
A. Novak,
S. Kumar,
J. A. Trapani, and P. I. Bird.
1998.
Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway.
Mol. Cell. Biol.
18:6387-6398[Abstract/Free Full Text].
|
| 10.
|
Bjorge, L.,
T. S. Jensen, and R. Matre.
1996.
Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.
Cancer Immunol. Immunother.
42:185-192[Medline].
|
| 11.
|
Boyd, A. W.,
S. O. Wawryk,
G. F. Burns, and J. V. Fecondo.
1988.
Intercellular adhesion molecule-1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms.
Proc. Natl. Acad. Sci. USA
85:3095-3099[Abstract/Free Full Text].
|
| 12.
|
Christiansen, D.,
J. Milland,
B. R. Thorley,
I. F. McKenzie, and B. E. Loveland.
1996.
A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro.
Eur. J. Immunol.
26:578-585[Medline].
|
| 13.
|
Dickinson, J. L.,
E. J. Bates,
A. Ferrante, and T. M. Antalis.
1995.
Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha induced apoptosis. Evidence for an alternate biological function.
J. Biol. Chem.
270:27894-27904[Abstract/Free Full Text].
|
| 14.
|
Dickinson, J. L.,
B. J. Norris,
P. H. Jensen, and T. M. Antalis.
1997.
The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF -induced apoptosis.
Cell Death Differ.
5:163-171.
|
| 15.
|
Garcia-Calvo, M.,
E. P. Peterson,
B. Leiting,
R. Ruel,
D. W. Nicholson, and N. A. Thornberry.
1998.
Inhibition of human caspases by peptide-based and macromolecular inhibitors.
J. Biol. Chem.
273:32608-32613[Abstract/Free Full Text].
|
| 16.
|
Greve, J. M.,
G. Davis,
A. M. Meyer,
C. P. Forte,
S. Connolly Yost,
C. W. Marlor,
M. E. Kamark, and A. McClelland.
1989.
The major human rhinovirus receptor is ICAM-1.
Cell
56:839-845[Medline].
|
| 17.
|
Karnauchow, T. M.,
D. L. Tolson,
B. A. Harrison,
E. Altman,
D. M. Lublin, and K. Dimmock.
1996.
The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55).
J. Virol.
70:5143-5152[Abstract/Free Full Text].
|
| 18.
|
Kinoshita, T.,
M. E. Medof,
R. Silber, and V. Nussenzweig.
1985.
Distribution of decay accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
J. Exp. Med.
162:75-92[Abstract/Free Full Text].
|
| 19.
|
Komatsu, T.,
Z. Bi, and C. S. Reiss.
1996.
Interferon-gamma induced type I nitric oxide synthase activity inhibits viral replication in neurons.
J. Neuroimmunol.
68:101-108[Medline].
|
| 20.
|
Kruithof, E. K. O.,
M. S. Baker, and C. L. Bunn.
1995.
Biological and clinical aspects of plasminogen activator inhibitor type 2.
Blood
86:4007-4024[Free Full Text].
|
| 21.
|
Kumar, S., and C. Baglioni.
1991.
Protection from tumour necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2.
J. Biol. Chem.
26:20960-20964.
|
| 22.
|
Langford, M. P.,
R. Crainic,
R. Vrijsen, and E. Wimmer.
1991.
Antibodies may act synergistically or additively with interferon to inhibit poliovirus.
Microb. Pathog.
10:419-427[Medline].
|
| 23.
|
Melnick, J. L.
1983.
Portraits of viruses: the picornaviruses.
Intervirology
20:61-100[Medline].
|
| 24.
|
Mendelsohn, C. L.,
E. Wimmer, and V. R. Racaniello.
1989.
Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily.
Cell
56:855-865[Medline].
|
| 25.
|
Minor, P. D.,
P. A. Pipkin,
D. Hockley,
G. C. Schild, and J. W. Almond.
1984.
Monoclonal antibodies which block cellular receptors of poliovirus.
Virus Res.
1:203-212[Medline].
|
| 26.
|
Moutabarrik, A.,
I. Nakanishi,
M. Namiki,
T. Hara,
M. Matsumoto,
M. Ishibashi,
A. Okuyama,
T. Zaid, and D. Seya.
1993.
Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55(DAF), and CD59 on human vascular endothelial cells.
Lymphokine Cytokine
12:167-172.
|
| 27.
|
Nakaya, N.,
M. Nishibori,
Z. Wang,
J. Sakiyama, and K. Saeki.
1998.
The expression and localization of serine proteinase inhibitor PI-6 mRNA in developmental and ischemic mouse brain.
Neurosci. Res.
3:221-230.
|
| 28.
|
Nicholson-Weller, A., and C. E. Wang.
1994.
Structure and function of decay accelerating factor CD55.
J. Lab. Clin. Med.
123:485-491[Medline].
|
| 29.
|
Roivainen, M., and L. Piirrainen.
1994.
Entry of coxsackievirus A9 into host cells: specific interactions with v 3 integrin, the vitronectin receptor.
Virology
203:357-365[Medline].
|
| 30.
|
Shafren, D. R.,
R. C. Bates,
M. V. Agrez,
R. L. Herd,
G. F. Burns, and R. D. Barry.
1995.
Coxsackieviruses B1, B3, and B5 use decay-accelerating factor as a receptor for cell attachment.
J. Virol.
69:3873-3877[Abstract].
|
| 31.
|
Shafren, D. R.,
D. J. Dohary,
S. J. Greive,
G. F. Burns, and R. D. Barry.
1997.
Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21.
J. Virol.
71:785-789[Abstract].
|
| 32.
|
Shafren, D. R.,
D. J. Dorahy,
R. A. Ingham,
G. F. Burns, and R. D. Barry.
1997.
Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry.
J. Virol.
71:4736-4743[Abstract].
|
| 33.
|
Shafren, D. R.,
D. T. Williams, and R. D. Barry.
1997.
A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.
J. Virol.
71:9844-9848[Abstract].
|
| 34.
|
Shafren, D. R.,
D. J. Dorahy,
R. F. Thorne,
T. Kinoshita,
R. D. Barry, and G. F. Burns.
1998.
Antibody binding to individual short consensus repeats of decay-accelerating factor enhance enterovirus binding and cell infection.
J. Immunol.
160:2318-2323[Abstract/Free Full Text].
|
| 34a.
|
Shafren, D. R.
1998.
Viral cell entry induced by cross-linked decay-accelerating factor.
J. Virol.
72:9407-9412[Abstract/Free Full Text].
|
| 35.
|
Subauste, X. C.,
D. B. Jacoby,
S. M. Richards, and D. Proud.
1995.
Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure.
J. Clin. Investig.
96:549-557.
|
| 35a.
| Suhrbier, A. Personal communication.
|
| 36.
|
Tomko, R. P.,
R. Xu, and L. Philipson.
1997.
HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses.
Proc. Natl. Acad. Sci. USA
94:3352-3356[Abstract/Free Full Text].
|
| 37.
|
Tosi, M. F.,
J. M. Stark,
C. W. Smith,
A. Hamedani,
D. C. Gruenert, and M. D. Infeld.
1992.
Induction of ICAM1 expression on human airway epithelial cells by inflammatory cytokines: effects on neutrophil-epithelial cell adhesion.
Am. J. Respir. Cell Mol. Biol.
7:214-221.
|
| 38.
|
Varsano, S.,
L. Rashkovsky,
H. Shapiro, and I. Radnay.
1998.
Cytokines modulate expression of cell-membrane complement inhibitory proteins in human lung cancer cell lines.
Am. J. Respir. Cell Mol. Biol.
19:522-529[Abstract/Free Full Text].
|
| 39.
|
Vassalli, J. D.,
A. P. Sappino, and D. Belin.
1991.
The plasminogen activator/plasmin system.
J. Clin. Investig.
88:1067-1072.
|
| 40.
|
Vassalli, P.
1992.
The pathophysiology of tumour necrosis factors.
Annu. Rev. Immunol.
10:411-452[Medline].
|
| 41.
|
Ward, T.,
P. A. Pipkin,
N. A. Clarkson,
D. M. Stone,
P. D. Minor, and J. W. Almond.
1994.
Decay accelerating factor CD55 is identified as the receptor for echovirus 7 using CELICS, a rapid immuno-focal cloning method.
EMBO J.
13:5070-5074[Medline].
|
| 42.
|
Wegner, C. D.,
R. H. Gundel,
P. Relly,
N. Haynes,
L. G. Letts, and R. Rothlein.
1990.
Intercellular adhesion molecule-1 (ICAM1) in the pathogenesis of asthma.
Science
247:456-459[Abstract/Free Full Text].
|
Journal of Virology, September 1999, p. 7193-7198, Vol. 73, No. 9
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Darnell, G. A., Schroder, W. A., Gardner, J., Harrich, D., Yu, H., Medcalf, R. L., Warrilow, D., Antalis, T. M., Sonza, S., Suhrbier, A.
(2006). SerpinB2 Is an Inducible Host Factor Involved in Enhancing HIV-1 Transcription and Replication. J. Biol. Chem.
281: 31348-31358
[Abstract]
[Full Text]
-
Darnell, G. A., Antalis, T. M., Rose, B. R., Suhrbier, A.
(2005). Silencing of Integrated Human Papillomavirus Type 18 Oncogene Transcription in Cells Expressing SerpinB2. J. Virol.
79: 4246-4256
[Abstract]
[Full Text]
-
Swartz, J. M., Bystrom, J., Dyer, K. D., Nitto, T., Wynn, T. A., Rosenberg, H. F.
(2004). Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes. J. Leukoc. Biol.
76: 812-819
[Abstract]
[Full Text]
-
Darnell, G. A., Antalis, T. M., Johnstone, R. W., Stringer, B. W., Ogbourne, S. M., Harrich, D., Suhrbier, A.
(2003). Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif. Mol. Cell. Biol.
23: 6520-6532
[Abstract]
[Full Text]
-
Yu, H., Stasinopoulos, S., Leedman, P., Medcalf, R. L.
(2003). Inherent Instability of Plasminogen Activator Inhibitor Type 2 mRNA Is Regulated by Tristetraprolin. J. Biol. Chem.
278: 13912-13918
[Abstract]
[Full Text]
-
Yu, H., Maurer, F., Medcalf, R. L.
(2002). Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. Blood
99: 2810-2818
[Abstract]
[Full Text]
-
Tierney, M. J., Medcalf, R. L.
(2001). Plasminogen Activator Inhibitor Type 2 Contains mRNA Instability Elements within Exon 4 of the Coding Region. SEQUENCE HOMOLOGY TO CODING REGION INSTABILITY DETERMINANTS IN OTHER mRNAs. J. Biol. Chem.
276: 13675-13684
[Abstract]
[Full Text]